NanoCarrier Co., Ltd. Reports Non-Consolidated Earnings Results for the Full Year Ended March 31, 2012; Provides Earnings Guidance for the First Half of Fiscal 2012; Provides Earnings Guidance for the Full Year Ending March 31, 2013
May 01, 2012
Share
NanoCarrier Co., Ltd. reported non-consolidated earnings results for the full year ended March 31, 2012. For the year, net sales were JPY 346 million against JPY 84 million a year ago. Operating loss was JPY 333 million against JPY 519 million a year ago. Net loss was JPY 398 million against JPY 555 million a year ago. Cash outflows from operation were JPY 293 million against JPY 579 million a year ago.
For the first half year of fiscal 2012, the company expects to report net sales of JPY 69 million, operating loss of JPY 529 million, net loss of JPY 531 million.
For the full year ending March 31, 2013, the company expects to report net sales of JPY 242 million, operating loss JPY 1,172 million and net loss of JPY 1,192 million.
Nano Mrna Co Ltd, formerly NanoCarrier Co Ltd, is mainly engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company develops businesses using the research and development of messenger ribonucleic acid (mRNA) medicine. The products under development are specialized in mRNA medicines. mRNA medicine is a medicine that prevents or treats diseases by administering artificially produced mRNA to the body and allowing the body to discover the protein encoded by the mRNA. Its pipeline includes RUNX1, the mRNA drug pipeline, non-mRNA drug pipeline, Comrex otological liquid 1.5%, NC-6100, TUG1, and others.
NanoCarrier Co., Ltd. Reports Non-Consolidated Earnings Results for the Full Year Ended March 31, 2012; Provides Earnings Guidance for the First Half of Fiscal 2012; Provides Earnings Guidance for the Full Year Ending March 31, 2013
NANO MRNA CO.,LTD. 
